Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies

AIM: To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). MATERIALS AND METHODS: DEPICT‐1 and ‐2 were randomized, double‐blind, parallel‐group, 24‐week studies, with 28‐week extension periods. Adults with T1D and HbA1c 7.5%‐10.5% were randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillip, Moshe, Mathieu, Chantal, Lind, Marcus, Araki, Eiichi, di Bartolo, Paolo, Bergenstal, Richard, Heller, Simon, Hansen, Lars, Scheerer, Markus Florian, Thoren, Fredrik, Arya, Niki, Xu, John, Iqbal, Nayyar, Dandona, Paresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839492/
https://www.ncbi.nlm.nih.gov/pubmed/33145944
http://dx.doi.org/10.1111/dom.14248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839492/
https://www.ncbi.nlm.nih.gov/pubmed/33145944
http://dx.doi.org/10.1111/dom.14248

Ejemplares similares